Differences in Expression of EGFR, Ki67 and p-EPK in Oral Cavity Squamous Cell Carcinoma
Purpose: To evaluate the expression of EGFR, Ki67, and p-EPK in oral cavity and oropharyngeal cancers, and to investigate their clinical significance as prognostic markers.
Methods: One hundred patients who underwent curative surgery for oral cavity or oropharyngeal squamous cell carcinoma in a Chinese People’s Liberation Army General Hospital between March 1999 and October 2010 were evaluated. The level of protein expression of EGFR, Ki67 and p-EPK was assessed by immunohistochemistry. In situ hybridization was used to detect the existence of human papillomavirus (HPV).
Results: Nineteen of 75 patients with oropharyngeal cancer showed HPV-positive tumors, and two of 72 patients with oral cavity cancer showed HPV-positive tumors. EGFR and Ki67 expression was significantly higher in oral cavity cancers than in oropharyngeal cancers (p = 0.005 and p = 0.001, respectively). Loss of p-EPK occurred significantly more frequently in oral cavity cancers than in oropharyngeal cancers (p = 0.004). Overexpression of EGFR and Ki67 and loss of p-EPK were observed more frequently in HPV negative tumors. Multivariate Cox regression analysis showed that Ki67 expression had a significantly unfavorable impact on relapse free survival in oropharyngeal cancer.
Conclusion: The expression levels of EGFR, Ki67, and p-EPK differ between oropharyngeal and oral cavity cancer and it may be attributed to HPV-related molecular pathogenesis. The expression of Ki67 might be an unfavorable prognostic marker for relapse-free survival in oropharyngeal cancer.
Keywords: EGFR; Ki67; p-EPK; Oral cavity squamous cell carcinoma, Expression difference
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.